Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/onc.2016.391 http://scihub22266oqcxt.onion/10.1038/onc.2016.391 C5415944!5415944!27775072     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncogene 2017 ; 36 (17): 2345-54 Nephropedia Template TP {{tp|p=27775072|t=2017. Metformin alters DNA methylation genome-wide via the H19/SAHH axis |pdf=|usr=}}{{27775072}} gab.com Text Metformin alters DNA methylation genome-wide via the H19/SAHH axis JO: Oncogene http://www.kidney.de/pget.php?&tw=1&pmid=27775072 #FOAvip The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line drug for type 2 diabetes, remain elusive. Here we report that metformin induces genome-wide alterations in DNA methylation by modulating the activity of S-adenosylhomocysteine hydrolase (SAHH). Exposing cancer cells to metformin leads to hypermethylation of tumor-promoting pathway genes and concomitant inhibition of cell proliferation. Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. H19 knockdown activates SAHH, enabling DNA methyltransferase 3B to methylate a subset of genes. This metformin-induced H19 repression and alteration of gene methylation are recapitulated in endometrial cancer tissue samples obtained from patients treated with antidiabetic doses of metformin. Our findings unveil a novel mechanism of action for the drug metformin with implications for the molecular basis of epigenetic dysregulation in cancer. This novel mechanism of action also may be occurring in normal cells. Twit Text FOAVip Metformin alters DNA methylation genome-wide via the H19/SAHH axis ????Oncogene http://www.kidney.de/pget.php?&tw=1&pmid=27775072 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27775072 #FOAvip English Wikipedia <ref>{{Cite pmid|27775072}}</ref> Metformin alters DNA methylation genome-wide via the H19/SAHH axis #MMPMID27775072 Zhong T; Men Y; Lu L; Geng T; Zhou J; Mitsuhashi A; Shozu M; Maihle NJ; Carmichael GG; Taylor HS; Huang Y Oncogene 2017[Apr]; 36 (17): 2345-54 PMID27775072show ga The molecular mechanisms underlying the antineoplastic properties of metformin, a first-line drug for type 2 diabetes, remain elusive. Here we report that metformin induces genome-wide alterations in DNA methylation by modulating the activity of S-adenosylhomocysteine hydrolase (SAHH). Exposing cancer cells to metformin leads to hypermethylation of tumor-promoting pathway genes and concomitant inhibition of cell proliferation. Metformin acts by upregulating microRNA let-7 through AMPK activation, leading to degradation of H19 long noncoding RNA, which normally binds to and inactivates SAHH. H19 knockdown activates SAHH, enabling DNA methyltransferase 3B to methylate a subset of genes. This metformin-induced H19 repression and alteration of gene methylation are recapitulated in endometrial cancer tissue samples obtained from patients treated with antidiabetic doses of metformin. Our findings unveil a novel mechanism of action for the drug metformin with implications for the molecular basis of epigenetic dysregulation in cancer. This novel mechanism of action also may be occurring in normal cells. äMetformin alters DNA methylation genome-wide via the H19/SAHH axis (epmc).pdf DeepDyve Pubget Overpricing